Harvard Bioscience Stock News

Cubist Systematic Strategies LLC bought a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 13,284 shares of the medical instruments suppliers stock, valued at approximately $111,000. A number of other hedge funds have also []

Nuveen Asset Management LLC lowered its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 29.0% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 124,164 shares of the medical instruments suppliers stock after selling 50,816 shares during the period. Nuveen Asset Management LLCs holdings []

Equities research analysts expect Harvard Bioscience, Inc. (NASDAQ:HBIO) to announce sales of $32.65 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Harvard Biosciences earnings. The lowest sales estimate is $32.50 million and the highest is $32.80 million. Harvard Bioscience posted sales of $30.98 million in the same quarter []

Charles Schwab Investment Management Inc. boosted its position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 116.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 206,655 shares of the medical instruments suppliers stock after purchasing an additional 111,169 shares during the []

Brokerages forecast that Harvard Bioscience, Inc. (NASDAQ:HBIO) will report $32.65 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Harvard Bioscience’s earnings. The lowest sales estimate is $32.50 million and the highest is $32.80 million. Harvard Bioscience posted sales of $30.98 million in the same quarter last […]

Analysts forecast that Harvard Bioscience, Inc. (NASDAQ:HBIO) will report earnings of $0.09 per share for the current quarter, Zacks reports. Two analysts have made estimates for Harvard Biosciences earnings. Harvard Bioscience reported earnings per share of $0.08 in the same quarter last year, which indicates a positive year-over-year growth rate of 12.5%. The firm is []

Rapid Micro Biosystems (NASDAQ:RPID) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Earnings & Valuation This table compares Rapid Micro Biosystems and Harvard Biosciences top-line revenue, []

Harvard Bioscience, Inc. (HBIO) CEO James Green on Q3 2021 Results - Earnings Call Transcript

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 5.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

HOLLISTON, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2021, before the market opens on N

Two new Breakout Stocks for Week 32 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges®, the portfolio is

Harvard Bioscience, Inc. (HBIO) CEO James Green on Q2 2021 Results - Earnings Call Transcript

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 20.00% and 6.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions

Does Harvard Bioscience (HBIO) have what it takes to be a top stock pick for momentum investors? Let's find out.